Polycystic ovary syndrome is a common disease of female reproductive dysfunction and endocrine and metabolic disorders, with a prevalence of about 6% to 8% in women of reproductive age. Obesity, insulin resistance, and hyperandrogenemia interact with each other to participate in its pathogenesis. Polycystic ovary syndrome is not only the main cause of anovulatory infertility in women, but also a cause of distant complications such as type 2 diabetes, hyperlipidemia, hypertension, coronary heart disease and estrogen-dependent malignancies, which seriously affect the quality of life of patients. Let’s get to know it together. Clinical manifestations of polycystic ovary syndrome Amenorrhea or scanty menstruation (irregular menstrual cycle ≥ 35 days), infertility, obesity (body mass index ≥ 25), hirsutism, etc. Treatment of polycystic ovary syndrome 1. Lifestyle adjustment: diet control, exercise and weight reduction; 2. Adjustment of menstrual cycle and prevention of endometrial hyperplasia (commonly used in mafron, dactin-35, estrogen and progestin simulating artificial cycle, etc.); 3. Treatment of hyperandrogenemia (commonly used in dactin-35); 4. (letrozole, HMG, etc.). The incidence of endometrial cancer, obesity, cardiovascular disease, blood pressure dyslipidemia, and type 2 diabetes mellitus are significantly higher in patients with PCOS than in normal subjects, so in addition to addressing fertility issues, patients with polycystic ovary syndrome need to prevent these long-term complications.